Foundation News

A dose-response trial of IV immunoglobulin in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)/DRIP study

K. Kuitwaard1,2, E Brusse1, A.F.J.E. Vrancken4, F. Eftimov5, N.C. Notermans4, A.J. van der Kooi5, I.S.J. Merkies6,7, B.C. Jacobs1,3, P.A. van Doorn1 1Department of Neurology, Erasmus MC, University Medical Center, Rotterdam, The Netherlands 2Department of Neurology, Albert Schweitzer Hospital, Dordrecht, The Netherlands 3Department of Immunology, Erasmus MC, University Medical Center, Rotterdam, The Netherlands 4Department of Neurology,…

Read More

The PATH Study

Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) and Treatment With Subcutaneous Immunoglobulin (IgPro20) The PATH Study was a trial that investigated immunoglobulin treatment infused with a pump into the tissue under the skin (subcutaneously). There are several advantage of subcutaneous over intravenous treatment, e.g. patients or their caregivers can treat themselves at home, there are less severe…

Read More

Japanese Ecuilizumab Trial for GBS

A new treatment with compliment inhibition improves motor function in Guillain- Barré syndrome: Japanese eculizumab trial for Guillain- Barré syndrome (JET-GBS) Recent basic studies on the pathophysiology of Guillain- Barré syndrome (GBS) have shown that complement activation has a major role on peripheral nerve damage in GBS. Eculizumab (Alexion Pharmaceuticals Inc) is a humanized monoclonal antibody…

Read More

IMAGiNe study

IgM paraprotein associated polyneuropathy is a slowly progressive disease with numbness or tingling of arms and legs and severe imbalance. Occasionally, tremors and weakness are present. These symptoms are disabling, but difficult to measure. In addition, the disease is relatively rare, not very well-known, and there is no cure available. The IMAGiNe study aims to…

Read More

Graham Cassidy Legislation Action Alert – We Need Your Help!

Dear Friends, As you are well aware, healthcare reform is constantly evolving. Advocacy is one of our four mission pillars and we are committed to representing the patient voice while keeping our community informed. While the Foundation remains non-partisan, our primary focus remains on patient protections and insuring access for necessary treatments. This current proposal…

Read More

CSL Behring Announces FDA Approval of Privigen®

CSL Behring Announces FDA Approval of Privigen® [Immune Globulin Intravenous (Human), 10% Liquid] for the Treatment of Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) in Adults KING OF PRUSSIA, Pa., Sept. 14, 2017 /PRNewswire/ — Global biotherapeutics leader CSL Behring today announced that the U.S. Food and Drug Administration (FDA) has approved Privigen® [Immune Globulin Intravenous (Human), 10% Liquid] for the treatment of…

Read More

Charity Navigator Names GBS|CIDP Foundation as ‘Charity Worth Watching’

10 Charities Worth Watching Many of America’s most effective charities are also household names. But some well-known charities are less effective than you’d think, while a number of lesser known charities are truly exceptional. These 10 charities all operate on less than $2 million a year, but they all earn a four-star rating from Charity Navigator….

Read More

Announcing the 2017 GBS|CIDP Foundation Grant Awardees

2017 GBS|CIDP Foundation Grant Awardees (#1) Title of the project: Enhance Peripheral Nerve Repair by Modulating Macrophage Subsets Investigator: Gang Zhang, M.D; Ph.D Assistant Professor of Neurology University of Texas, Health Sciences Center at Houston Synopsis: Intravenous immunoglobulin (IVIg) is now the first-line therapy for Guillain-Barré syndrome (GBS). However, there are many disadvantages including high cost, supply…

Read More

Marketplace Access Project Applauds Bipartisan Letter from 181 Members of Congress Urging HHS to Protect Life-Saving Charitable Patient Assistance

Letter Introduced by Reps. Kevin Cramer (R-ND) & Doris Matsui (D-CA) Seeks to Protect Quarter of a Million Americans Who Depend on Charitable Assistance for Access to Critical Healthcare WASHINGTON, D.C. (May 31, 2017) – The Marketplace Access Project (MAP), a group of leading national patient advocacy organizations dedicated to protecting non-profit insurance premium and…

Read More

GBS|CIDP Foundation International 2017 Benson Clinical Research Fellowship

GBS|CIDP Foundation International 2017 Benson Clinical Research Fellowship   The GBS|CIDP Foundation International is pleased to announce a competition for the second Benson Clinical Research Fellowship.  The aim of the scheme is to provide funds (up to $150k per year for three years) to enable clinicians or non-clinical scientists in training or having recently completed training…

Read More

Largest Ever CIDP Clinical Study Completed

Largest Ever CIDP Clinical Study Completed PATH study evaluated subcutaneous immunoglobulin efficacy and safety for treating Chronic Inflammatory Demyelinating Polyneuropathy KING OF PRUSSIA, Pa. – 01 March 2017 – Global biotherapeutics leader CSL Behring announced today that it has completed the largest ever Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) trial, known as PATH (Polyneuropathy And Treatment…

Read More

GBS|CIDP Foundation International Named to the 2016 Classy 100

GBS|CIDP Foundation International Named to the 2016 Classy 100 Recognized as a consistent growing nonprofit on the leading online fundraising platform in 2016   Narberth, Pennsylvania –  GBS|CIDP Foundation International made this year’s Classy 100 list, an annual compilation of the growing nonprofits on Classy, the world’s leading online fundraising platform for social enterprises. Classy…

Read More

7th Interlaken Leadership Awards

  Interlaken Leadership Awards The Interlaken Leadership Awards support original research in the field of neuroimmunology. Investigators whose proposals are approved by the review committee will receive monetary grants and/or drug supply. The size of the individual grants is not predetermined, in order to accommodate a wide variety of investigator needs. However small innovative trials…

Read More

Pagination